Novartis and Suzhou-based Abogen Biosciences announced Oct. 2 a licensing deal centered on Novartis Abogen mRNA candidate ABO2203—an mRNA-encoded CD19×CD3 T-cell engager—worth $575 million upfront and up to roughly $7.2 billion in milestones, or about $7.8 billion if options across Abogen’s RNA platform are fully exercised.
Deal terms for the Novartis Abogen mRNA program
Per BioSpace and Abogen’s press release, Novartis gains exclusive worldwide rights to ABO2203 plus exclusive options on additional RNA-platform programs. Abogen may also earn royalties on future sales. The transaction still needs customary regulatory clearances. Fierce Biotech notes the agreement arrives weeks after Novartis paused an autoimmune CAR-T program after patient deaths.
How ABO2203 works inside the body
ABO2203 is a lipid nanoparticle–formulated mRNA that instructs a patient’s own cells to produce a CD19×CD3 T-cell engager in vivo, aiming to deplete disease-driving B cells in autoimmune settings. Abogen argues the in-body approach could lower cytokine release syndrome risk compared with many recombinant engagers that carry boxed CRS warnings. Early ITP and B-cell non-Hodgkin lymphoma signals cited by Abogen included B-cell depletion without CRS in small cohorts; partners have not locked a single lead indication in the Friday release.
China dealmaking and Boston-area biotech context
A Novartis spokesperson told BioSpace the company was drawn to Abogen’s RNA platform and mRNA-encoded engager work, consistent with CEO Vas Narasimhan’s “geography-agnostic” deal stance. The Abogen pact follows other Novartis China licenses this year and sits beside broader lab-AI and regional pharma coverage such as Microsoft Quine’s biology AI for lab discovery, Lundbeck’s Boston headquarters move, and Project Suncatcher’s space-bound AI chips.
What comes next
Investors will watch closing conditions, which Abogen options Novartis exercises, and whether autoimmune or oncology cohorts expand first. For patients, the near-term story is still early clinical signal plus a large platform option—not an approved therapy.
Sources: BioSpace; Fierce Biotech; Abogen.